August 15, 2001
* NetGuru Inc., a Yorba Linda information technology company, reported that its net loss for the first quarter widened to $1.2 million, or 7 cents a share, from $300,000, or 4 cents a share, a year earlier. Revenue fell 7% to $6.8 million. * Lake Forest collectibles company L.L. Knickerbocker Co. reported second-quarter profit of $180,000, contrasted with a net loss of $671,000, or 1 cent a share, for the comparable period last year. Sales declined 24% to $6.7 million.
August 8, 2001
Nexell Therapeutics Inc. in Irvine said Tuesday it agreed to sell its cell-processing business to its biggest shareholder, Baxter International, for $4.3 million, plus unspecified royalties on future product sales. Nexell announced the transaction in June, but financial details were not disclosed. Nexell's remaining work force was reduced by 18 employees. The companies expect to complete the transaction by Oct. 1, Nexell said.
June 13, 2001 |
Struggling Nexell Therapeutics Inc. said Tuesday that it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc. The Irvine developer of cell therapies to treat cancer and other diseases said Baxter's health care unit will obtain worldwide sales and marketing and distribution rights for Nexell's flagship Isolex magnetic cell-selection system, cell culture and storage containers, and other products.
May 16, 2001
Collectibles company L.L. Knickerbocker Co. Inc. in Lake Forest reported a net loss $1.2 million, or 2 cents a share, for the first quarter, compared with a loss of $1.4 million, or 3 cents a share, a year earlier. Sales declined 25% to $5.4 million . . . Nexell Therapeutics Inc., an Irvine biotechnology company, posted a loss $6.1 million, or 39 cents a share, for the first quarter, compared with a net loss of $7.7 million, or 51 cents a share, for the first quarter of 2000.
April 25, 2001 |
A federal district court judge in Delaware awarded AmCell Corp. a partial summary judgment in a patent infringement suit filed by Nexell Therapeutics Inc. in March 2000, over rival cell-separation devices. Judge Rodrick McKelvie told AmCell, a U.S.
March 22, 2001 |
Nexell Therapeutics Inc. said Wednesday that it will seek Food and Drug Administration approval to start its own trial of engineered stem-cell grafts, based on the results of a study conducted by the National Institutes of Health. The Irvine biotechnology company said in a press release that the previous study showed "marked improvement" in the immune function of patients with chronic granulomatous disease, or CGD, despite the death of three volunteers.